Nøkkelinformasjon ved kontantutbytte for Wilson ASA
- Utbyttebeløp: 4,50
- Annonsert valuta: NOK
- Siste dag inklusive: 11. november 2022
- Ex-dato: 14. november 2022
- Record date (eierregisterdato): 15. november 2022
- Betalingsdato: 30 november 2022
- Vedtaksdato: 9. november 2022
Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12Hvis du vil se dette innholdet fra www.globenewswire.com, gi ditt samtykke øverst på denne siden.
Hvis du vil se dette innholdet fra ml-eu.globenewswire.com, gi ditt samtykke øverst på denne siden.
Om GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeldinger fra GlobeNewswire by notified
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire by notified på epost fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra GlobeNewswire by notified
Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis8.12.2022 10:12:00 CET | Press release
8 December 2022 Clinigen notesresults from the MIROCALS trial investigating low doseProleukin® (aldesleukin)in patients withamyotrophic lateral sclerosis Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, is pleased to notethe announcement of top-line results from MIROCALS (Modifying Immune Response & OutComes in Amyotrophic Lateral Sclerosis) a phase 2b randomised placebo-controlled trial investigating the efficacy and safety of low dose interleukin-2 (ld IL-2) for controlling neuro-inflammation in newly-diagnosed patients with amyotrophic lateral sclerosis (ALS). The MIROCALS trial, conducted in 220 patients from 17 clinics across the UK and France, in collaboration with eight leading research groups in the UK, France, Italy and Sweden, investigated whether low dose IL-2 can modify aspects of neuro- inflammation, which is believed to play a central role in ALS disease progression. Dr. Gilbert Bensimon presented the top-line results at the International Symposi
Kvika banki hf.: Birkir Jóhannsson new CEO of TM8.12.2022 10:01:44 CET | Press release
Birkir Jóhannsson has been appointed CEO of TM, Kvika banki‘s subsidiary. Birkir will be replacing Sigurður Viðarsson as he takes up the position of deputy CEO at Kvika. Birkir has in past years worked as managing director of core operations and digital solutions at VIS Insurance and has substantial work experience within banking, payment solutions and finance. Birkir has previously been employed at Birti Capital Partners, Valitor, Arion bank and Attorneys atHöfðabakki.. Birkir holds a law degree from the University of Iceland and a master’s degree in corporate finance from Reykjavik University. In addition, Birkir has completed a degree in securities trading and is licensed as a district court attorney. Birkir will be a member of the Kvika group management board. When the changes, that Kvika banki introduced on 5 December, have been implemented the Kvika group management team will consist of Kvika banki’s management board, the CEO of TM, the CEO of Kvika asset management and the CEO o
EV-Joyment, Emotional Promise Motivate EV Adoption Over Environmental Benefits8.12.2022 10:00:58 CET | Press release
Latest Escalent EVForward™ Europe report findings encourage brands to tap into emotional aspirations of BEV ownership to engage with consumers LIVONIA, Mich., Dec. 08, 2022 (GLOBE NEWSWIRE) -- As new-car buyer personas continue to evolve, connecting with consumers’ emotions and personality is more likely to ignite interest in battery electric vehicles (BEVs). This diverges from the long-standing industry narrative that environmental benefits are what drive BEV adoption, creating great opportunity for brands to expand their messaging and embrace new customers with a varying mix of values, lifestyles and attitudes. The environmental and running cost credentials of BEVs are clear, but relatively few car buyers are motivated by such a narrow range of rational criteria. In 2022, 43% of car buyers acknowledge the environmental credentials of BEVs as a benefit, but the same factor only ranks 9th out of 19 in a hierarchy of most important car buying criteria, thus revealing the environment’s l
Two rental housing trends reflected in SATO data too: Rental housing in city centres and residential districts remains popular − Most rental households have one or two members8.12.2022 10:00:00 CET | Press release
SATO Corporation Press release 8 December 2022 at 11.00 am The most popular residential areas are found in growth centre districts and areas close to city centres. One in three SATO tenants live alone. In late October, Statistics Finland released data on types of housing in Finland*, with two trends emerging from the statistics: the number of both those renting a home and those living alone is increasing. These trends can also be seen in data collected by SATO, one of Finland’s largest rental housing providers**. Population growth continues in the Helsinki Metropolitan Area, Tampere and Turku, and already almost half of the households in these cities live in a rental home. There are several reasons behind the popularity of renting a home in growth centres, including demographic change, the uncertainties of working life and the differentiated price development of owner-occupied homes: Outside growth centres, the real prices of homes are declining, which makes acquiring an owner-occupied
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP8.12.2022 10:00:00 CET | Press release
12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II bipolar disorder New data from COMPASS’ phase 2b trial, also presented at ACNP, validate potential of COMP360 psilocybin therapy in treatment-resistant depression LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that new positive data demonstrating the potential of COMP360 psilocybin therapy in depression have been presented at the Annual Meeting of the American College of Neuropsychopharmacology (ACNP). The results were presented from an investigator-initiated, exploratory open-label study of investigational COMP360 psilocybin therapy in type II bipolar disorder and a mechanistic analysis of the phase 2b trial of CO